Literature DB >> 34511756

Mitral valve repair in chronic severe mitral regurgitation: short-term results and analysis of mortality predictors.

Vinitha Viswambharan Nair1, Syam Das2, Ramesh Bhaskaran Nair2, Thomas Pandarakalam George3, Joseph Thomas Kathayanat1, Nidheesh Chooriyil1, Ratish Radhakrishnan1, Jayakumar Thanathu Krishnan Nair1.   

Abstract

INTRODUCTION: Mitral valve repair is the accepted treatment for mitral regurgitation (MR) but lack of resources and socioeconomic concerns delay surgical referral and intervention in developing countries. We evaluated immediate and short-term results of mitral valve repair for non-ischemic MR at our centre and aimed to identify the predictors of in-hospital and follow-up mortality.
MATERIALS AND METHODS: The study was conducted at a tertiary-level hospital in South India. All patients >18 years with severe non-ischemic MR who underwent mitral valve repair over a period of 6 years were included. Perioperative data was collected from hospital records and follow-up data was obtained by prospective methods.
RESULTS: There were 244 patients (170 males). Most of the patients were in the age group 31-60 years (76.6%). Aetiology of MR was degenerative (n = 159; 65.2%), rheumatic (n = 34; 13.9%), structural (n = 42; 17.2%), or miscellaneous (n = 9; 3.7%). All patients underwent ring annuloplasty with various valve repair techniques. One hundred patients (44.7%) underwent additional cardiac procedures. At discharge, MR was moderate in 4 patients; the rest had no or mild MR. The mean hospital stay of survivors was 7.1 days (SD 2.52, range 5-25 days). There were 9 in-hospital deaths (3.68%) and 10 deaths during follow-up (4.2%). The mean follow-up period was 1.39 years, complete for 87.6%. Pre-operative left ventricle ejection fraction (LVEF) <60% (p = 0.04) was found to be significantly associated with immediate mortality. Logistic regression analysis detected age (p = 0.019), female sex (p = 0.015), and left ventricular (LV) dysfunction at discharge (p = 0.025) to be significantly associated with follow-up mortality.
CONCLUSION: Pre-operative LV dysfunction was identified as a significant risk factor for in-hospital mortality. Female sex, age greater than 45 years, and LV dysfunction at discharge were found to be significantly associated with follow-up mortality. Hence, it is important to perform mitral valve repair in severe regurgitation patients before significant LV dysfunction sets in for a better outcome. © Indian Association of Cardiovascular-Thoracic Surgeons 2021.

Entities:  

Keywords:  Left ventricular dysfunction; Mitral regurgitation; Mitral valve repair

Year:  2021        PMID: 34511756      PMCID: PMC8387534          DOI: 10.1007/s12055-021-01160-x

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  22 in total

1.  Results of mitral valve repair in rheumatic mitral regurgitation.

Authors:  Arkalgud Sampath Kumar; Sachin Talwar; Anita Saxena; Rajvir Singh; Devagourou Velayoudam
Journal:  Interact Cardiovasc Thorac Surg       Date:  2006-04-03

2.  Changes in left ventricular morphology and function after mitral valve surgery.

Authors:  Alexis E Shafii; A Marc Gillinov; Tomislav Mihaljevic; William Stewart; Lillian H Batizy; Eugene H Blackstone
Journal:  Am J Cardiol       Date:  2012-04-23       Impact factor: 2.778

3.  Benefits of Early Surgery on Clinical Outcomes After Degenerative Mitral Valve Repair.

Authors:  Tianyu Zhou; Jun Li; Hao Lai; Kai Zhu; Yongxin Sun; Wenjun Ding; Tao Hong; Chunsheng Wang
Journal:  Ann Thorac Surg       Date:  2018-06-05       Impact factor: 4.330

4.  Growing importance of valvular heart disease in the elderly.

Authors:  Yan Chen; Kai-Hang Yiu
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

5.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

6.  Changes in left ventricular function after mitral valve repair for severe organic mitral regurgitation.

Authors:  Tomasz G Witkowski; James D Thomas; Victoria Delgado; Eva van Rijnsoever; Arnold C T Ng; Ulas Hoke; See H Ewe; Dominique Auger; Kai H Yiu; Eduard R Holman; Robert J M Klautz; Martin J Schalij; Jeroen J Bax; Nina Ajmone Marsan
Journal:  Ann Thorac Surg       Date:  2012-01-31       Impact factor: 4.330

7.  Predicting left ventricular dysfunction after valve repair for mitral regurgitation due to leaflet prolapse: additive value of left ventricular end-systolic dimension to ejection fraction.

Authors:  Christophe Tribouilloy; Dan Rusinaru; Catherine Szymanski; Sonia Mezghani; Alexandre Fournier; Franck Lévy; Marcel Peltier; Ammar Ben Ammar; Doron Carmi; Jean-Paul Remadi; Thierry Caus; Gilles Touati
Journal:  Eur J Echocardiogr       Date:  2011-08-04

8.  Improvement in left ventricular dysfunction after surgical correction of mitral regurgitation.

Authors:  Antônio Sérgio Cordeiro da Rocha; Nazareth de Novaes da Rocha; Rita de Cássia Villela Soares; Marialda Coimbra; Rosana Grandelle Ramos; Clara Weksler; Fernando Eugênio Cruz Filho; Celso Garcia da Silveira; Paulo Roberto Dutra da Silva
Journal:  Arq Bras Cardiol       Date:  2003-02-19       Impact factor: 2.000

9.  Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease.

Authors:  Tirone E David; Susan Armstrong; Brian W McCrindle; Cedric Manlhiot
Journal:  Circulation       Date:  2013-03-04       Impact factor: 29.690

10.  Early surgery versus conventional treatment for asymptomatic severe mitral regurgitation: a propensity analysis.

Authors:  Duk-Hyun Kang; Sung-Ji Park; Byung Joo Sun; Eun Jeong Cho; Dae-Hee Kim; Sung-Cheol Yun; Jong-Min Song; Seung Woo Park; Cheol-Hyun Chung; Jae-Kwan Song; Jae-Won Lee; Pyo-Won Park
Journal:  J Am Coll Cardiol       Date:  2014-03-30       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.